Lilly’s Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

Eli Lilly's investigational oral GLP-1 agonist, orforglipron, met primary and key secondary endpoints in two recent phase 3 diabetes trials, showing significant weight loss and improvements in cardiovascular risk factors5 4.

One trial compared orforglipron directly to dapagliflozin (Farxiga), while another compared it to placebo; orforglipron demonstrated clinical superiority in both studies for glycemic control and weight loss5 7.

Orforglipron also outperformed oral semaglutide (Novo Nordisk’s Reybelsus) in a head-to-head diabetes study; analysts suggest it may become the first commercially successful oral GLP-1 due to efficacy, safety, tolerability, and flexible dosing without food restrictions2 4 9.

Patients in the studies experienced up to 10.5% average weight loss, and the drug showed an advantageous profile for treating overweight, obesity, and type 2 diabetes4 8 9.

Lilly plans to submit orforglipron for obesity approval by the end of 2025 and for type 2 diabetes in 20263 5.

Experts believe orforglipron could become a new standard of care in type 2 diabetes management if approved, given its head-to-head clinical wins and broad patient applicability5 4.